Compare Davita Inc (DVA) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Sea Limited — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Sea Limited trades at $95.15 (market cap $56.89B). The key difference: Sea Limited is far larger — about 5× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Sea Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Sea Limited for 102 Days on average.
| DVA | SE | |
|---|---|---|
Market Cap | $11.29B | $56.89B |
Volume | 582,204 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $188.00 |
52-Week Low | $103.87 | $78.16 |
Typical Hold Time | 113 Days | 102 Days |
Enterprise Value | $24.01B | $51.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Sea Limited (SE) trades at $94.66, down 1.94% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental progress with revenue growing from $12.4B in 2022 to $22.9B in 2025 and achieving profitability, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $153.67 consensus price target, representing significant upside potential from current levels.
Sea presents a compelling growth story with expanding profitability and strong e-commerce momentum, though execution risks and competitive pressures persist. The stock's current valuation at 36.55x P/E reflects growth expectations, while technical weakness suggests potential near-term consolidation. Institutional confidence remains high despite recent insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
